# FIGHT-203 (NCT03011372)

> A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

No report yet. It can be ordered.

- Drugs tested: pemigatinib
- Indication: myeloid/lymphoid neoplasms with FGFR1 rearrangement

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03011372
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Incyte Corporation
- Conditions: MPN (Myeloproliferative Neoplasms)
- Interventions: Pemigatinib
- Enrollment: 47
- Primary outcome: Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

## Indexed commentary on FIGHT-203 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=fight-203-nct03011372